Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jules Bordet Institute
The primary objective of this study was to evaluate the feasibility of implementing Genomic Grade Index (GGI) in community hospitals in Belgium for breast cancer patients with node negative and 1-3 node positive early breast cancer. GGI would be considered a feasible genomic test if results were obtained in \> 70% of evaluated patients.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed invasive breast cancer meeting the following criteria:
T1, T2, or operable T3 disease
Zero to three positive lymph nodes and no distant metastases
Operable disease - Must have undergone breast-conserving surgery or mastectomy with either a sentinel node procedure or full axillary clearance
You may not be if
No other invasive cancer within the past 5 years except for adequately treated carcinoma in situ of the cervix or non melanoma skin cancer
No psychological, familial, sociological, or geographical condition that would preclude entering into a clinical study
Clareo Health | Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer
